QuickView for Prochlorperazine (compound)

Summary
General Info

PubChem

PubChem Compound 4917

Name:	Prochlorperazine
PubChem Compound ID:	4917
Description:	A phenothiazine antipsychotic used principally in the treatment of NAUSEA; VOMITING; and VERTIGO. It is more likely than CHLORPROMAZINE to cause EXTRAPYRAMIDAL DISORDERS. (From Martindale, The Extra Pharmacopoeia, 30th ed, p612)
Molecular formula:	C₂₀H₂₄ClN₃S
Molecular weight:	373.943 g/mol
Synonyms:	Chlorperazine; EINECS 200-379-4; Prochlorpermazine; MLS000028600; Nipodal; RP 6140; AIDS-031700; Prochlorperazine dihydrobromide; Compro; Bayer A 173. show more » Chlorperazine; EINECS 200-379-4; Prochlorpermazine; MLS000028600; Nipodal; RP 6140; AIDS-031700; Prochlorperazine dihydrobromide; Compro; Bayer A 173; Prochlorperazin; Meterazin; KBio2_001320; SPBio_001333; Spectrum3_000881; Temetid; Spectrum2_001297; KBio2_004872; 2-Chloro-10-(3-(4-methyl-1-piperazinyl)propyl)-10H-phenothiazine; NSC665801; KBio3_001762; KBio2_006456; KBioSS_001320; Compro (TN); Prochlorperazinum [INN-Latin]; Chlormeprazine; DivK1c_000413; Prestwick1_000399; Vertigon hydrochloride; 6140 RP; Stemetil; 10H-Phenothiazine, 2-chloro-10-[3-(4-methyl-1-piperazinyl)propyl]-; Prochlorperazine Edisylate; Tementil; 3-Chloro-10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazine; CAS-84-02-6; N-(gamma-(4'-Methylpiperazinyl-1')propyl)-3-chlorophenothiazine; NSC17478; Meterazine; Spectrum_000840; KBio2_002304; KBioSS_002306; Kronocin; Proclorperazine; AIDS-001622; NCI60_022783; KBioGR_002304; 2-Chloro-10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazine; NINDS_000413; Novamin; Procloperazine; 10H-Phenothiazine, 2-chloro-10-(3-(4-methyl-1-piperazinyl)propyl)-; Eskatrol; Tementil dihydrobromide; Compazine Suppositories; Compazine (Maleate); KBio1_000413; Capazine; Emelent; HSDB 3171; Proclorperazina [INN-Spanish]; AIDS031700; Prochlorpemazine; D00493; Chloro-3 (N-methylpiperazinyl-3 propyl)-10 phenothiazine [French]; SMR000058705; Lopac-P-9178; Spectrum4_000972; KBio2_003888; SKF 4657; NCGC00015856-01; NCGC00015856-02; Vertigon; KBioGR_001343; KBio2_007440; Prochlorperazine (JAN/USP); Prochlorperazine [USAN:BAN:INN:JAN]; AIDS001622; CHLOPERAZINE; 3-Chloro-10-(3-(1-methyl-4-piperazinyl)propyl)phenothiazine; Prochlorperazine; 2-Chloro-10-(3-(1-methyl-4-piperazinyl)propyl)-phenothiazine; 58-38-8; Phenothiazine, 2-chloro-10-(3-(4-methyl-1-piperazinyl)propyl)-; SPBio_002538; 84-02-6; KBio3_002784; Chlorperazine dihydrobromide; Prestwick0_000399; Compazine; 1257-78-9; Prochlorpromazine; C07403 show less «

DrugBank

Identification

Name:	Prochlorperazine
Name (isomeric):	DB00433
Drug Type:	small molecule
Description:	A phenothiazine antipsychotic used principally in the treatment of NAUSEA; VOMITING; and VERTIGO. It is more likely than CHLORPROMAZINE to cause EXTRAPYRAMIDAL DISORDERS. (From Martindale, The Extra Pharmacopoeia, 30th ed, p612)
Synonyms:	Chlorperazine; Chlormeprazine; Prochlorperazine maleate; Prochlorperazine edisylate; Proclorperazine; Prochloroperazine; Prochlorperazin; Procloperazine; Prochlorpromazine; Prochlorpemazine
Brand:	Combid, Tementil, Capazine, Nipodal, Eskatrol, Emetiral, Compazine, Meterazin, Stemetil, Emelent, Meterazin Maleate, Meterazine, Kronocin, Bayer A 173, Pasotomin, Buccastem, Compro, Novamin, Vertigon, Temetid
Category:	Phenothiazines, Antiemetics, Dopamine Antagonists, Antipsychotic Agents, Antipsychotics
CAS number:	58-38-8

Pharmacology

Indication:	For the symptomatic management of psychotic disorders, short term management of nonpsychotic anxiety in patients with generalized anxiety disorder, and for the control of severe nausea and vomiting of various causes.
Pharmacology:	Prochlorperazine is a piperazine phenothiazine related to high-potency neuroleptics such as perphenazine. It shares many of the actions and adverse effects of the antipsychotics.
Mechanism of Action:	The mechanism of action of prochlorperazine has not been fully determined, but may be primarily related to its antidopaminergic effects. Prochlorperazine blocks the D2 somatodendritic autoreceptor, resulting in the blockade of postsynaptic dopamine receptors in the mesolimbic system and an increased dopamine turnover. Prochlorperazine also has anti... show more » The mechanism of action of prochlorperazine has not been fully determined, but may be primarily related to its antidopaminergic effects. Prochlorperazine blocks the D2 somatodendritic autoreceptor, resulting in the blockade of postsynaptic dopamine receptors in the mesolimbic system and an increased dopamine turnover. Prochlorperazine also has anti-emetic effects, which can be attributed to dopamine blockade in the chemoreceptor trigger zone. Prochlorperazine also blocks anticholinergic and alpha-adrenergic receptors, the blockade of alpha(1)-adrenergic receptors resulting in sedation, muscle relaxation, and hypotension. show less «
Absorption:	Rapidly absorbed following oral administration
Protein binding:	91-99%
Biotransformation:	Hepatic. Undergoes metabolism in the gastric mucosa and on first pass through the liver, CYP2D6 and/or CYP3A4.
Half Life:	6 to 8 hours
Toxicity:	Symptoms of central nervous system depression to the point of somnolence or coma. Agitation and restlessness may also occur. Other possible manifestations include convulsions, EKG changes and cardiac arrhythmias, fever and autonomic reactions such as hypotension, dry mouth and ileus; LD₅₀=400mg/kg (orally in mice)
Affected organisms:	Humans and other mammals

Interactions

Food interaction:

Take with a full glass of water Avoid excessive quantities of coffee or tea (Caffeine).

Avoid alcohol.

Take with food.

Drug interaction:

Grepafloxacin	Increased risk of cardiotoxicity and arrhythmias
Levofloxacin	Increased risk of cardiotoxicity and arrhythmias
Methamphetamine	Decreased anorexic effect, may increase pyschotic symptoms
Metrizamide	Increased risk of convulsions
Phenylpropanolamine	Decreased anorexic effect, may increase psychotic symptoms.

Grepafloxacin	Increased risk of cardiotoxicity and arrhythmias
Levofloxacin	Increased risk of cardiotoxicity and arrhythmias
Methamphetamine	Decreased anorexic effect, may increase pyschotic symptoms
Metrizamide	Increased risk of convulsions
Phenylpropanolamine	Decreased anorexic effect, may increase psychotic symptoms.
Sparfloxacin	Increased risk of cardiotoxicity and arrhythmias
Tetrabenazine	May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects.
Guanethidine	Prochlorperazine may decrease the effect of guanethidine.
Bromocriptine	The phenothiazine decreases the effect of bromocriptine
Donepezil	Possible antagonism of action
Fenfluramine	Decreased anorexic effect, may increase psychotic symptoms.
Benzphetamine	Antipsychotics may diminish the stimulatory effect of Amphetamines. Monitor effectiveness of amphetamine therapy when altering concurrent antipsychotic therapy as antipsychotic agents may impair the stimulatory effect of amphetamines.
Terfenadine	Increased risk of cardiotoxicity and arrhythmias
Diethylpropion	Decreased anorexic effect, may increase psychotic symptoms.
Galantamine	Possible antagonism of action
Phenmetrazine	Decreased anorexic effect, may increase pyschotic symptoms
Mazindol	Decreased anorexic effect, may increase psychotic symptoms.
Triprolidine	The antihistamine, Triprolidine, may increase the arrhythmogenic effect of the phenothiazine, Prochlorperazine. Monitor for symptoms of ventricular arrhythmias. Additive anticholinergic and CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
Dextroamphetamine	Decreased anorexic effect, may increase pyschotic symptoms
Phendimetrazine	Decreased anorexic effect, may increase pyschotic symptoms
Tacrine	The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Prochlorperazine, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents.
Amphetamine	Decreased anorexic effect, may increase pyschotic symptoms
Gatifloxacin	Increased risk of cardiotoxicity and arrhythmias
Trospium	Trospium and Prochlorperazine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
Phentermine	Decreased anorexic effect, may increase psychotic symptoms.
Rivastigmine	Possible antagonism of action
Trimethobenzamide	Trimethobenzamide and Prochlorperazine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
Cisapride	Increased risk of cardiotoxicity and arrhythmias
Dexfenfluramine	Decreased anorexic effect, may increase psychotic symptoms.

show less «

Targets

D(2) dopamine receptor

Enzymes

Cytochrome P450 2D6

Cytochrome P450 3A4